Compositions and formulations for treatment of gastrointestinal tract malabsorption diseases and inflammatory conditions and methods of production and use thereof
Nutritive polypeptides are provided herein. Also provided are various other embodiments including nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions and formulations that comprise the polypeptides, and methods of using the polypeptides, compositions and formulations.
1. A method of treating a gastrointestinal protein malabsorption disease, disorder or condition in a human subject in need thereof, comprising administering to the human subject a nutritional formulation in an amount sufficient to treat such disease, disorder or condition, wherein the nutritional formulation comprises an isolated nutritive polypeptide comprising the sequence shown in SEQ ID NO: 240; wherein the formulation is present as a liquid, semi-liquid or gel in a volume not greater than about 500 ml or as a solid or semi-solid in a total mass not greater than about 200 g.
2. The method of claim 1 , wherein the isolated nutritive polypeptide has an aqueous solubility at pH 7 of at least 12.5, 20, 30, 50, or 100 g/L.
3. The method of claim 1 , wherein the isolated nutritive polypeptide has a simulated gastric digestion half-life of less than 2, 10, 30, or 60 minutes.
4. The method of claim 1 , wherein the isolated nutritive polypeptide does not form insoluble aggregates at 95° C., pH 7.1, when present at 10 mg/ml.
5. The method of claim 1 , wherein the formulation further comprises a pharmaceutically acceptable carrier.
6. The method of claim 1 , wherein the formulation further comprises a component selected from the group consisting of a tastant, a protein mixture, a polypeptide, a peptide, a free amino acid, a carbohydrate, a lipid, a mineral or mineral source, a vitamin, a supplement, an organism, a pharmaceutical, and an excipient.
7. The method of claim 1 , wherein the human subject has a dysphagia selected from the group consisting of an oropharyngeal dysphagia, an esophageal dysphagia, and a functional dysphagia.
8. The method of claim 1 , wherein the nutritive formulation is administered in an amount effective to increase serum albumin and/or a serum clotting factor in the human subject following administration.
9. The method of claim 1 , wherein the nutritive formulation is administered in an amount effective to reduce inflammatory infiltrate in the gastrointestinal tract of the human subject following administration.
10. The method of claim 1 , wherein the human subject has a gastrointestinal disorder or a short bowel syndrome gastrointestinal disorder.
11. The method of claim 1 , wherein the nutritional formulation is administered in conjunction with an exercise regimen, or wherein the nutritional formulation is administered as an adjunct to a surgical procedure.
12. The method of claim 1 , wherein the subject is immobilized or mobility-impaired following a surgical procedure.
13. The method of claim 1 , wherein the nutritional formulation is administered as an adjunct to administration of a pharmaceutical composition.
14. The method of claim 1 , wherein the human subject has an eating disorder.